Allicin, an Emerging Treatment for Pulmonary Arterial Hypertension: An Experimental Study
International Journal of Molecular Sciences · 19.08.2023 · 24 (16) · 12959
DOI: 10.3390/ijms241612959 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.08.2023. Verfasst von José L Sánchez-Gloria und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, Rush University Medical Center, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Nacional de Cardiología Ignacio Chávez.
Abstract (Originalsprache)
We assessed whether allicin, through its antihypertensive and antioxidant effects, relieves vascular remodeling, endothelial function, and oxidative stress (OS), thereby improving experimental pulmonary arterial hypertension (PAH). Allicin (16 mg/kg) was administered to rats with PAH (monocrotaline 60 mg/kg). Allicin encouraged body weight gain and survival rate, and medial wall thickness and the right ventricle (RV) hypertrophy were prevented. Also, angiotensin II concentrations in the lung (0.37 ± 0.01 vs. 0.47 ± 0.06 pmoles/mL, allicin and control, respectively) and plasma (0.57 ± 0.05 vs. 0.75 ± 0.064, allicin and control respectively) and the expressions of angiotensin-converting enzyme II and angiotensin II type 1 receptor in lung tissue were maintained at normal control levels with allicin. In PAH rats treated with allicin, nitric oxide (NO) (31.72 ± 1.22 and 51.4 ± 3.45 pmoles/mL), tetrahydrobiopterin (8.43 ± 0.33 and 10.14 ± 0.70 pmoles/mL), cyclic guanosine monophosphate (5.54 ± 0.42 and 5.64 ± 0.73 pmoles/mL), and Ang-(1-7) (0.88 ± 0.23 and 0.83 ± 0.056 pmoles/mL) concentrations increased in lung tissue and plasma, respectively. In contrast, dihydrobiopterin increase was prevented in both lung tissue and plasma (5.75 ± 0.3 and 5.64 ± 0.73 pmoles/mL); meanwhile, phosphodiesterase-5 was maintained at normal levels in lung tissue. OS in PAH was prevented with allicin through the increased expression of Nrf2 in the lung. Allicin prevented the lung response to hypoxia, preventing the overexpression of HIF-1α and VEGF. Allicin attenuated the vascular remodeling and RV hypertrophy in PAH through its effects on NO-dependent vasodilation, modulation of RAS, and amelioration of OS. Also, these effects could be associated with the modulation of HIF-1α and improved lung oxygenation. The global effects of allicin contribute to preventing endothelial dysfunction, remodeling of the pulmonary arteries, and RV hypertrophy, preventing heart failure, thus favoring survival. Although human studies are needed, the data suggest that, alone or in combination therapy, allicin may be an alternative in treating PAH if we consider that, similarly to current treatments, it improves lung vasodilation and increase survival. Allicin may be considered an option when there is a lack of efficacy, and where drug intolerance is observed, to enhance the efficacy of drugs, or when more than one pathogenic mechanism must be addressed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Nephrology, Rush University Medical Center, Chicago, IL 60612, USA.
- Experimental Pathology Department, Experimental Pathology Laboratory, Instituto Nacional de Ciencia Médicas y Nutrición "Salvador Zubirán", Mexico City 14080, Mexico.
- Departamento de Farmacología "Dr. Rafael Méndez Martínez", Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
- Departamento de Fisiopatología Cardio-Renal, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
- Departamento de Inmunología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
ORCID-Profile: Constanza E Martínez-Olivares, Fernando Cortés-Camacho, Rogelio Hernández-Pando, Fausto Sánchez-Muñoz, Horacio Osorio-Alonso
Förderung
- Instituto Nacional de Cardiología Ignacio Chávez
Zitieren
APA
Sánchez-Gloria, J. L., Martínez-Olivares, C. E., Del Valle-Mondragón, L., Cortés-Camacho, F., Zambrano-Vásquez, O. R., Hernández-Pando, R., Sánchez-Muñoz, F., Sánchez-Lozada, L. G., & Osorio-Alonso, H. (2023). Allicin, an Emerging Treatment for Pulmonary Arterial Hypertension: An Experimental Study. International Journal of Molecular Sciences, 24(16), 12959. https://doi.org/10.3390/ijms241612959
Vancouver
Sánchez-Gloria JL, Martínez-Olivares CE, Del Valle-Mondragón L, Cortés-Camacho F, Zambrano-Vásquez OR, Hernández-Pando R, et al. Allicin, an Emerging Treatment for Pulmonary Arterial Hypertension: An Experimental Study. International Journal of Molecular Sciences. 2023;24(16):12959. doi:10.3390/ijms241612959
BibTeX
@article{SnchezGloria2023,
author = {Sánchez-Gloria, José L and Martínez-Olivares, Constanza E and Del Valle-Mondragón, Leonardo and Cortés-Camacho, Fernando and Zambrano-Vásquez, Oscar R and Hernández-Pando, Rogelio and Sánchez-Muñoz, Fausto and Sánchez-Lozada, Laura G and Osorio-Alonso, Horacio},
title = {Allicin, an Emerging Treatment for Pulmonary Arterial Hypertension: An Experimental Study},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {16},
pages = {12959},
doi = {10.3390/ijms241612959}
}
EUVIMED